| Ticker Symbol: | GPRO |
|---|---|
| Exchange: | NASD |
| Contact Info: | 10210 Genetic Center Drive San Diego CA 92121-4362 858 410-8000 |
| CEO/President: | Henry L. Nordhoff |
| Industry: | Medical - Biomedical / Standard Industry Code: 3841 |
| Description: | Gen-Probe Inc. is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid testing (NAT) products used for the clinical diagnosis of human diseases and for screening donated human blood. Using its patented NAT technology, Gen-Probe has received FDA approvals for more than 40 products that detect a wide variety of infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, pneumonia and fungal infections. |
| Shares Outstanding: | 54,210 (000) | Market Value: | 2,323,610 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 93.17% | Number of Inst.Shareholders: | 2.00% |
| Last Quarter Sales: | 121.18 ($Mil.) | Last Quarter Net Income: | 29.08 ($Mil.) |
| Last Quarter EPS: | 0.53 | P/E Ratio: | 22 |
| Most Recent Earnings: | 0.53 on 10/30/08 | Earnings Per Share: | 1.93 |
| Most Recent Split: | 2-1 on 10/01/03 | Annual Dividend Rate: | 0 |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |


| AMGEN | +12.60 | 58.23 | |
| GILEAD SCIENCES | -1.00 | 46.92 | |
| CELGENE CP | -10.00 | 58.86 | |
| BIOGEN IDEC INC | -31.90 | 43.52 | |
| AMYLIN PHARMA I | -85.70 | 6.41 |
